Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons

BioArctic Sweden

View original content:https://www.prnewswire.co.uk/news-releases/lecanemab-deliberations-at-the-chmp-regarding-the-marketing-authorisation-application-in-the-eu-have-been-rescheduled-due-to-procedural-reasons-302097048.html